Medicenna Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	10.61	24.84	16.98	33.6	20.54	30.38
Short-Term Investments	-	-	-	-	-	10.01
Cash & Short-Term Investments	10.61	24.84	16.98	33.6	20.54	40.39
Cash Growth	-64.61%	46.26%	-49.45%	63.60%	-49.15%	7.12%
Other Receivables	1.47	2.7	1.16	0.86	1.31	0.41
Total Trade Receivables	1.47	2.7	1.16	0.86	1.31	0.41
Other Current Assets	0.84	0.64	0.93	1.93	1.55	1.35
Total Current Assets	12.91	28.17	19.08	36.39	23.39	42.15
Net Property, Plant & Equipment	0.1	0.16	-	-	-	0.03
Other Intangible Assets	0.05	0.05	0.06	0.06	0.07	0.07
Total Assets	13.07	28.38	19.13	36.45	23.46	42.25
Accounts Payable	4.76	4.39	2.86	3.8	2.62	4.07
Current Portion of Leases	0.07	0.05	-	-	-	0.03
Total Current Liabilities	4.82	4.44	2.86	3.8	2.62	4.11
Long-Term Leases	0.07	0.12	-	-	-	-
Other Long-Term Liabilities	1.96	4.73	11.08	3.16	-	-
Total Long-Term Liabilities	2.03	4.85	11.08	3.16	-	-
Total Liabilities	6.85	9.29	13.94	6.96	2.62	4.11
Common Stock	126.26	126.13	100.92	100.92	83.67	79.59
Additional Paid-in Capital	12.33	11.22	10.7	9.49	7.93	6.68
Accumulated Other Comprehensive Income	0.05	0	0.02	0.06	0.17	0.23
Retained Earnings	-132.43	-118.25	-106.45	-80.98	-70.93	-48.36
Shareholders' Equity	6.21	19.1	5.19	29.49	20.84	38.15
Total Liabilities & Equity	13.07	28.38	19.13	36.45	23.46	42.25
Total Debt	0.14	0.17	0	0	0	0.03
Net Cash (Debt)	10.48	24.67	16.98	33.6	20.54	40.35
Net Cash Growth	-57.52%	45.27%	-49.45%	63.60%	-49.11%	7.22%
Net Cash Per Share	0.13	0.32	0.24	0.52	0.38	0.81
Book Value	6.21	19.1	5.19	29.49	20.84	38.15
Book Value Per Share	0.08	0.25	0.07	0.46	0.38	0.77
Tangible Book Value	6.16	19.04	5.13	29.43	20.77	38.07
Tangible Book Value Per Share	0.08	0.25	0.07	0.45	0.38	0.77